Evotec/EVO

$5.25

-4.37%
-
1D1W1MYTD1YMAX

About Evotec

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Ticker

EVO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mario Polywka

Employees

-

Headquarters

Hamburg, Germany

Evotec Metrics

BasicAdvanced
$2B
Market cap
-
P/E ratio
-
EPS
1.50
Beta
-
Dividend rate
$2B
1.50449
$13.49
$4.87
124K

What the Analysts think about Evotec

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
143.81% upside
High $19.00
Low $4.00
$5.25
Current price
$12.80
Average price target

Evotec Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 49.55%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.04
-$0.04
-$0.12
-$0.05
-
Expected
$0.11
-$0.04
-$0.05
-$0.03
-$0.10
Surprise
-140.76%
10.94%
149.25%
49.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Evotec stock?

Evotec (EVO) has a market cap of $2B as of May 18, 2024.

What is the P/E ratio for Evotec stock?

The price to earnings (P/E) ratio for Evotec (EVO) stock is 0 as of May 18, 2024.

Does Evotec stock pay dividends?

No, Evotec (EVO) stock does not pay dividends to its shareholders as of May 18, 2024.

When is the next Evotec dividend payment date?

Evotec (EVO) stock does not pay dividends to its shareholders.

What is the beta indicator for Evotec?

Evotec (EVO) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Evotec stock price target?

The target price for Evotec (EVO) stock is $12.8, which is 143.81% above the current price of $5.25. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Evotec stock

Buy or sell Evotec stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing